Differential Contribution of the Guanylyl Cyclase-Cyclic GMP-Protein Kinase G Pathway to the Proliferation of Neural Stem Cells Stimulated by Nitric Oxide

Bruno P. Carreira, Maria Inês Morte, Ana Sofia Lourenço, Ana Isabel Santos, Ângela Inácio, António F. Ambrósio, Caetana M. Carvalho, Inês M. Araújo

Centre for Neuroscience and Cell Biology, Neuroendocrinology and Neurogenesis Group and Centre of Ophthalmology and Vision Sciences, IBILI, Faculty of Medicine, University of Coimbra, Coimbra, and Department of Biomedical Sciences and Medicine, University of Algarve, Faro, Portugal

Key Words
Nitric oxide · Neural stem cells · cyclic GMP · cGMP-dependent kinase · Proliferation · Neurogenesis · Guanylyl cyclase

Abstract
Nitric oxide (NO) is an important inflammatory mediator involved in the initial boost in the proliferation of neural stem cells following brain injury. However, the mechanisms underlying the proliferative effect of NO are still unclear. The aim of this work was to investigate whether cyclic GMP (cGMP) and the cGMP-dependent kinase (PKG) are involved in the proliferative effect triggered by NO in neural stem cells. For this purpose, cultures of neural stem cells isolated from the mouse subventricular zone (SVZ) were used. We observed that long-term exposure to the NO donor (24 h), NOC-18, increased the proliferation of SVZ cells in a cGMP-dependent manner, since the guanylate cyclase inhibitor, ODQ, prevented cell proliferation. Similarly to NOC-18, the cGMP analogue, 8-Br-cGMP, also increased cell proliferation. Interestingly, shorter exposures to NO (6 h) increased cell proliferation in a cGMP-independent manner via the ERK/MAP kinase pathway. The selective inhibitor of PKG, KT5823, prevented the proliferative effect induced by NO at 24 h but not at 6 h. In conclusion, the proliferative effect of NO is initially mediated by the ERK/MAPK pathway, and at later stages by the GC/cGMP/PKG pathway. Thus, our work shows that NO induces neural stem cell proliferation by targeting these two pathways in a biphasic manner.

Introduction
An injury to the central nervous system often results in neuroinflammation, which is characterized by the activation of resident microglial cells, astrocytes, and eventually by infiltrating peripheral macrophages and lymphocytes, recently reviewed by Whitney et al. [1]. It is now well established that inflammation affects the formation of new cells following brain injury [2–4]. An acute brain insult, such as stroke, seizures, or trauma, often elicits a proliferative response from the neurogenic niches [5–9]. New cells are attracted to the lesioned areas in order to replace the lost neural cells [10]. Factors
produced and released by immune cells during the neuroinflammatory response affect the proliferation, migration, and differentiation of neuronal precursors following a lesion [11, 12]. Microglial cells can produce a wide range of pro- and anti-inflammatory mediators, which can differentially affect the different steps of neurogenesis [2, 3, 13]. Among such factors, nitric oxide (NO) is of particular interest given its notable features such as short half-life, diffusivity, and signaling properties [1].

NO is a free radical produced by NO synthases and a pleiotropic messenger in several biological processes [14]. Recent studies have shown the involvement of NO on neurogenesis, either in basal conditions or following an injury. Particularly, NO was described as a physiological inhibitor of neurogenesis in mice [15–18]. Other studies demonstrated that NO is important for the initial increase in proliferation of neural stem cells in the neurogenic niches following stroke [19] or seizures [20]. We recently showed that the NO donor 2,2′-(hydroxytrinitrosohydrozino)bis-ethanamine (NOC-18) can stimulate proliferation of isolated neural stem cells in culture when used in low doses (1–10 μM) [20]. Nevertheless, the mechanisms underlying the proliferative effect of NO are not yet identified.

The main biological target of NO is the heme-containing enzyme guanylyl cyclase. Guanylyl cyclase catalyzes the conversion of GTP to cyclic GMP (cGMP), which in turn can act on further downstream targets such as the cGMP-dependent kinase (PKG) and cGMP-gated channels. In a variety of cell types, NO and cGMP have been described as important effectors in several cellular processes, including survival, differentiation, growth, axon guidance or migration, through the activation of different downstream signaling cascades [21–23]. Neurogenesis is positively affected by cGMP and cGMP-sparing agents such as sildenafil or tadalafil [21, 24–26]. However, it remains to be established whether cGMP and PKG are responsible for the proliferative effect of NO when applied to neural stem cells. Within this scenario, we investigated the role of the guanylyl cyclase-cGMP-PKG pathway in the proliferative effect of NO. We observed that cGMP analogues mimic the effect of NO in increasing cell proliferation. Moreover, blocking guanylyl cyclase or PKG prevented the proliferative effect of NO, thus pointing to the involvement of the NO-cGMP signaling pathway in the enhancement of neural stem cell proliferation.

### Materials and Methods

#### Materials

Dulbecco’s modified Eagle’s medium:F-12 nutrient mixture (D-MEM/F-12, with GlutaMAX™-T), B27 supplement, trypsin-EDTA solution (0.05% trypsin, 1 mM EDTA in Hanks balanced salt solution, antibiotic (10,000 units/ml penicillin, 10 mg/ml streptomycin), epidermal growth factor, basic fibroblast growth factor and Click-iT® EdU Alexa Fluor® 488 Flow Cytometry Assay Kit were purchased from Invitrogen (Paisley, UK). 5-Bromo-2′-deoxyuridine (BrdU), 8-bromoguanosine 3′,5′-cyclic monophosphate (8-Br-cGMP), phenylmethylsulfonyl fluoride, dithiothreitol, orthovanadate, chymostatin, leupatin, pepstatin A, trypan blue and 1,4-diamino-2,3-dicyano-1,4-bis(o-amino-phenylmercaptobutadieneno) monothiolate (U0126) were purchased from Sigma Chemical (St. Louis, Mo., USA). KT5823 was purchased from Alomone Labs (Jerusalem, Israel). 1H-[1,2,4]oxadiazolo[4,3-a]quinolin-1-one (ODQ) and zaprinast were obtained from Tocris Bioscience (Bristol, UK). Mouse anti-Sox-2 was purchased from R&D Systems (Minneapolis, Minn., USA) and rabbit anti-nestin from Santa Cruz Biotechnology (Santa Cruz, Calif., USA). NOC-18 was obtained from Alexis Biochemicals (San Diego, Calif., USA). A DAKO fluorescence mounting medium was purchased from DakoCytomation (Glostrup, Denmark). Rat anti-mouse BrdU was obtained from Oxford Biotechnology (Oxford, UK). Hoechst 33342 dye, anti-rat IgG conjugated with Alexa Fluor 594, anti-mouse IgG conjugated with Alexa Fluor 594 and anti-rabbit IgG conjugated with Alexa Fluor 488 secondary antibodies were purchased from Molecular Probes (Leiden, The Netherlands). Polyvinylidene difluoride membranes, enhanced chemiluminescence reagent, cGMP BioTRAK, alkaline phosphatase-linked anti-rabbit and anti-mouse secondary antibodies were obtained from Amersham Pharmacia Biotec (Little Chalfont, UK). Monoclonal mouse anti-p44/42 MAPK (ERK1/2) and rabbit anti-phospho-ERK1/2 antibodies were obtained from Cell Signaling Technology (Danvers, Mass., USA). Other reagents used in immunoblotting experiments were purchased from BioRad (Hercules, Calif., USA).

#### Animals

C57BL/6 mice were obtained from Charles River (Barcelona, Spain) and kept with food and water ad libitum in a 12-hour dark:light cycle. All experiments were performed in accordance with the NIH and the European (86/609/EEC) guidelines for the care and use of laboratory animals.

#### Subventricular Zone Neural Stem Cell Cultures

Neuronal stem cell cultures were obtained from the subventricular zone (SVZ) of postnatal day 0–3 C57BL/6 mice, as previously described [20]. Briefly, the brains were removed from the skull following decapitation, and placed in a dissection medium composed of Ca2+ - and Mg2+-free Hanks balanced salt solution (137 mM NaCl, 5.36 mM KCl, 0.44 mM KH2PO4, 0.34 mM Na2PO4, 2H2O, 4.16 mM NaHCO3, 5 mM glucose, 1 mM sodium pyruvate, 10 mM HEPES, pH 7.4), supplemented with 0.25% gentamicin. After removing the enveloping meninges, the cerebellum was discarded and the whole cortex tissue was cut in 450-μm-thick coronal sections using a MclLwain tissue chopper (The Mickle Laboratory Engineering Co. Ltd., Guildford, UK). The fragments of SVZ encompassing both ependymal and subependymal layers were digested in 0.025% tryp-
Characterization of SVZ Primary Cultures

SVZ-derived neural stem cells plated on poly-L-lysine-coated coverslips for 5 days (in a minimum of 3 independent experiments) were fixed with 4% paraformaldehyde/4% sucrose in phosphate-buffered saline (PBS, 0.1 M). The cells were then permeabilized with 1% Triton X-100 for 5 min. Nonspecific binding was blocked with 3% BSA in 0.2% Tween 20 in PBS (PBS-T) for 1 h, and cells were labeled with the primary antibodies mouse anti-Sox-2 (1:100) and rabbit anti-nestin (1:100) for 90 min at room temperature. The cells were then exposed to secondary antibodies anti-mouse and anti-rabbit IgGs conjugated with Alexa Fluor 594 (1:200), respectively, for 1 h at room temperature. Nuclei were stained with Hoechst 33342 (1 μg/ml) for 3 min. Coverslips were mounted on glass slides using a DAKO fluorescence mounting medium. Images were acquired in a laser scanning microscope LSM 510 META (Zeiss, Jena, Germany).

Experimental Treatments in SVZ Cell Cultures

SVZ-derived neural stem cells were exposed to the NO donor NOC-18 (10 μM) or to the cGMP analogue 8-Br-cGMP (20 μM) for different periods of time, as indicated in detail in the figure legends and in the text. The guanylyl cyclase inhibitor ODQ (50 μM), the protein kinase G (PKG) inhibitor KT5823 (1 μM) or the MEK1/2 inhibitor U0126 (1 μM) were added 30 min before NOC-18 or 8-Br-cGMP and kept throughout the incubation period.

Dose-composed NOC-18 was was diluted by diluting a 10 mM NOC-18 stock solution (prepared in 0.01 M NaOH, which keeps NOC-18 from releasing NO in alkaline solutions) to 1 mM NOC-18 in a culture medium (pH 7.0, since NOC-18 releases NO at this pH), which was kept for 72 h at room temperature on a lab bench, unprotected from light. This solution was used to treat SVZ cultures in a final concentration of 10 μM decomposed NOC-18, and experiments were run with fresh NOC-18.

Determination of cGMP Levels

The cGMP levels in SVZ-derived neural stem cell cultures were determined after exposure to drugs for 6 or 24 h using a cGMP enzyme immunoassay system (Amersham). All experiments were carried out in duplicate and in the presence of zaprinast (50 μM), a phosphodiesterase inhibitor, as previously described [27]. Cell lysis and cGMP measurement were performed according to the manufacturer’s instructions. The results are expressed as femtomoles per million cells.

Detection of Cell Proliferation and Cell Cycle Analysis by Flow Cytometry

SVZ cell proliferation was assessed by the incorporation of 5-ethyl-2'-deoxyuridine (EdU) and detected by flow cytometry, using the Click-IT EdU Alexa Fluor 488 Flow Cytometry Assay Kit. EdU was added to the SVZ cultures 4 h before fixation. Fixation was performed with 70% ethanol overnight. Detection of EdU incorporation was based on click chemistry, a copper-catalyzed reaction between an azide (conjugated to a fluorophore) and an alkyne (EdU). Fixed cells were incubated for 30 min with Alexa Fluor 488 azide and copper sulfate. The cells were then incubated with RNase and the nuclear dye 7-actinomycin D (7-AAD) for 30 min. The cells were analyzed for EdU incorporation and nuclear staining on a FACScalibur using the CellQuest software (Becton Dickinson, San Jose, Calif., USA). Thirty thousand events were acquired per experiment. A minimum of 3 independent experiments were analyzed for each condition. The flow cytometer was calibrated with fluorescent standard microbeads (CalibRITE Beads, BD Biosciences, San Jose, Calif., USA) for accurate instrument setting.

Detection of BrdU Incorporation

Cell proliferation was also assessed by the incorporation of the thymidine analogue BrdU, which is incorporated into the DNA of dividing cells during S phase. BrdU (10 μM) was added to the cultures 16 h before fixation [20, 28]. Nuclei that incorporated BrdU in this time window were detected by immunofluorescence as follows: following 20 min fixation with 4% paraformaldehyde/4% sucrose in PBS, the cells were permeabilized with 1% Triton X-100 for 5 min, and DNA was denaturated by treatment with 1 M HCl for 30 min at 37°C. Nonspecific binding was blocked with 3% BSA in PBS-T for 1 h, and then BrdU-positive cells were labeled with a rat anti-BrdU antibody (1:50) for 90 min at room temperature. The cells were then incubated with a secondary antibody goat anti-rat IgG conjugated with Alexa Fluor 594 (1:200) for 1 h at room temperature. Nuclei were stained with Hoechst 33342 (1 μg/ml) for 3 min. Coverslips were mounted on glass slides using DAKO fluorescence mounting medium Dako Cytomation. The cells were visualized in a fluorescence microscope (Axioskop 2 Plus, Zeiss, Jena, Germany) and images were acquired with the Axiosvision software 4.7. The number of BrdU-positive nuclei was counted in 7–10 randomly selected fields for each coverslip (in a total of approximately 900–1,200 cells per coverslip), and the data were expressed as percentages of the total number of living cells. A minimum of 3 independent experiments were analyzed for each condition.

Western Blot Analysis

Cells were lysed in 50 mM Tris-HCl, 10 mM EGTA, 1% Triton X-100 and 2 mM MgCl2, supplemented with 100 μM phenylmethylsulfonyl fluoride, 1 mM diithothreitol, 1 μg/ml chymostatin, 1 μg/ml leupeptin, 1 μg/ml antipain, 5 μg/ml pepstatin A, 1 mM sodium orthovanadate, and 50 mM NaF, pH 7.4, at 4°C. Protein concentration was determined by the bicinchoninic acid method (BCA™ Protein Assay kit, Pierce, Rockford, Ill., USA), and the samples were used for Western blot analysis, after adding 6X concentrated sample buffer (0.5 M Tris, 30% glycerol, 10% sodium dodecyl sulfate, 0.6 M diithothreitol, 0.012% bromophenol blue) and heating, for 5 min, at 95°C. Equal amounts of protein were separated by electrophoresis on sodium dodecyl sulfate-poly-
acrylamide gels, and transferred electrophoretically to polyvi-
lydene difluoride membranes. These were then blocked for 1 h at
room temperature in Tris-buffered saline (137 mM NaCl, 20 mM
Tris-HCl, pH 7.6) containing 0.1% Tween 20 (TBS-T) and 3% BSA.
Incubations with primary antibodies (rabbit anti-phospho-
ERK1/2 or mouse anti-ERK1/2, 1:1,000; Cell Signaling, Danvers,
Mass., USA) in TBS-T 1% BSA were performed overnight at 4°C.
The membranes were subsequently incubated for 1 h at room tem-
perature with alkaline phosphatase-linked secondary antibodies
(anti-rabbit or anti-mouse IgG, 1:20,000) in TBS-T 1% BSA. After
extensive washing in TBS-T with 0.5% BSA, immunoreactive
bands were visualized on a VersaDoc 3000 Imaging System (Bio-
Rad, Hercules, Calif., USA) following incubation of the mem-
brane with enhanced chemifluorescence reagent for 5 min. The
results are expressed as the percentage of control of phospho-
ERK/total ERK ratio.

Statistical Analysis
Data are expressed as means ± SEM. Statistical significance
was determined by using two-tailed t tests or one-factor analysis
of variance (ANOVA) as appropriate, followed by post hoc Bonferroni’s or Dunnet’s tests, as indicated in the figure legends and
in the text. Differences were considered significant when p < 0.05.

Results

Characterization of SVZ Primary Cultures
Cells isolated from the SVZ were cultured as described
previously (see Materials and Methods), and plated on
poly-L-lysine-coated coverslips for 5 days. At this stage
the cells were immunoreactive for the transcription fac-
tor Sox-2, essential for the self-renewal of undifferenti-
ated stem cells, and nestin, a neural precursor cell mark-
er. The percentage of double-labeled cells was approxi-
mately 70%, suggesting that the majority of cells remain
undifferentiated before being used for experiments
(fig. 1). This abundance of undifferentiated SVZ cells is
similar to that observed in SVZ primary cultures used in
previous studies investigating the effects of NO on cell
proliferation by our group [20] as well as by others [18,
29].

NO Increases Cell Proliferation via the Guanylyl
Cyclase-cGMP Pathway
To investigate the involvement of cGMP in the prolif-
erative effect of NO, we evaluated the incorporation of
thymidine analogues (EdU or BrdU) by SVZ cell cultures
following treatment with a NO donor (NOC-18). We have
previously shown that treatment with NOC-18 in the
range of 1–10 μM increases proliferation of SVZ cells, but
whether cGMP is involved in NO-induced neural stem
cell proliferation has not been addressed. We first inves-
tigated, by flow cytometry, the involvement of cGMP in
the proliferative effect of NO after 6 or 24 h following
treatment with NOC-18 (10 μM). Exposure to NOC-18 for
6 h increased the incorporation of EdU to 133.4 ± 5.12%
of the control (p < 0.001) (fig. 2a). After 24 h of NOC-18
treatment we further increased the EdU incorporation to
165.3 ± 10.2% of the control (p < 0.001) (fig. 2b). In con-
trol conditions (untreated cells) the percentage of EdU-
positive cells (percentage of total living cells) was 2.4 ±
0.7% at 6 h and 2.2 ± 0.9% at 24 h.

The involvement of cGMP in the proliferative effect of
NOC-18 was evaluated using the guanylyl cyclase inhibi-
tor ODQ. Treatment with ODQ prevented NO-induced
EdU incorporation at 24 h (p < 0.05), compared to SVZ
cells treated with NOC-18 alone (fig. 2b), suggesting that
cGMP mediates the effect of NO on cell proliferation for
Table 1. Determination of cGMP levels in neural stem cell cultures following exposure to NOC-18 for 6 or 24 h

<table>
<thead>
<tr>
<th>Treatment</th>
<th>cGMP levels, fmol/10⁶ cells</th>
</tr>
</thead>
<tbody>
<tr>
<td>6 h</td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td>23.3 ± 3.6</td>
</tr>
<tr>
<td>NOC-18</td>
<td>257.8 ± 70.1*</td>
</tr>
<tr>
<td>NOC-18 + ODQ</td>
<td>25.2 ± 3.5*</td>
</tr>
<tr>
<td>ODQ</td>
<td>25.8 ± 2.1</td>
</tr>
<tr>
<td>24 h</td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td>52.4 ± 3.4</td>
</tr>
<tr>
<td>NOC-18</td>
<td>266.3 ± 16.7**</td>
</tr>
<tr>
<td>NOC-18 + ODQ</td>
<td>25.9 ± 8.7**</td>
</tr>
<tr>
<td>ODQ</td>
<td>25.2 ± 11.9</td>
</tr>
<tr>
<td>NOC-18 + U0126</td>
<td>308.1 ± 32.7*</td>
</tr>
<tr>
<td>U0126</td>
<td>46.3 ± 19.3</td>
</tr>
</tbody>
</table>

Data are expressed as means ± SEM of 2–4 independent experiments. SVZ cells were treated with NOC-18 (10 μM) with or without ODQ (50 μM), or U0126 (1 μM). ODQ and U0126 were added before and kept throughout exposure to NOC-18.

Fig. 2. NO increases cell proliferation via the guanylyl cyclase-cGMP pathway for longer (24 h) but not for shorter (6 h) periods of cell exposure to NO. Cell proliferation following treatment with NOC-18 (10 μM) in the absence or presence of 50 μM ODQ for 6 h (a) or 24 h (b), evaluated by the incorporation of EdU and assessed by flow cytometry. Data are expressed as means ± SEM of at least 6 independent experiments. One-way ANOVA (Bonferroni’s post-test). *p < 0.001 or **p < 0.01, significantly different from control; ***p < 0.001, significantly different from NOC-18. EdU incorporation in neural stem cells following exposure to NOC-18 (10 μM) in the absence or presence of 1 μM U0126, a selective MEK1 and MEK2 inhibitor, for 6 h (c) or 24 h (d), as assessed by flow cytometry. Data are expressed as means ± SEM of at least 4 independent experiments. One-way ANOVA (Bonferroni’s post-test). *p < 0.05 or **p < 0.001, significantly different from control; ***p < 0.001, significantly different from NOC-18. Representative images of BrdU (red) incorporation in neural stem cells following exposure to NOC-18 (10 μM) for 24 h in the absence or presence of a guanylyl cyclase inhibitor, ODQ (50 μM). Nuclei are labeled by Hoechst 33342 (blue). Scale bar: 20 μm. ODQ completely blocks the increase in the number of BrdU-positive cells. Data are expressed as means ± SEM of at least 4 independent experiments. One-way ANOVA (Bonferroni’s post-test). ***p < 0.001, significantly different from control; +++p < 0.001, significantly different from 10 μM NOC-18. Decomposed NOC-18 (D-NOC-18) does not stimulate proliferation of SVZ-derived neural stem cells, unlike fresh NOC-18. Data are expressed as means ± SEM of at least 4 independent experiments. One-way ANOVA (Dunnet’s post-test). ***p < 0.001, significantly different from control. Colors refer to the online version only.

The cGMP Analogue 8-Br-cGMP Mimics the Proliferative Effect of NOC-18

Since cGMP appears to mediate the proliferative effect of NO at 24 h, we assessed the proliferative effect of a
Biphasic Stimulation of Neural Stem Cell Proliferation by NO

NO-Induced Activation of the Guanylyl Cyclase Pathway Is Independent of ERK/MAPK Pathway Activation

To identify the intracellular pathways that mediate the proliferative effect of NO, we investigated whether the guanylyl cyclase pathway is involved in the activation of the ERK/MAPK pathway. We showed that NOC-18 alone stimulates proliferation of SVZ cultures by activating ERK1/2 [20]. To evaluate how fast the phosphorylation of ERK1/2 occurs following exposure to NOC-18, we analyzed the phospho-ERK1/2/total ERK1/2 immunoreactivity ratio at several time points after the stimulus (at 5, 15, 30 and 60 min). The phosphorylation of ERK1/2 transiently increased to 138.1 ± 8.4% of the control at 15 min after exposure to NOC-18. The phosphorylation of ERK1/2 then transiently decreased to 50.6 ± 3.3% of the control at 60 min (Fig. 4).

Cell viability was assessed using the nuclear dye 7-AAD, detected by flow cytometry. Data are expressed as means ± SEM of at least 3 independent experiments. p > 0.05 (nonsignificant; n.s.), not different from control, one-way ANOVA (Dunnett’s post-test).

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Live cells</th>
</tr>
</thead>
<tbody>
<tr>
<td>6 h Control</td>
<td>90.9 ± 1.4%</td>
</tr>
<tr>
<td>10 μM NOC-18</td>
<td>90.0 ± 1.7% (n.s.)</td>
</tr>
<tr>
<td>10 μM NOC-18 + 1 μM U0126</td>
<td>90.2 ± 1.9% (n.s.)</td>
</tr>
<tr>
<td>1 μM U0126</td>
<td>92.6 ± 1.2% (n.s.)</td>
</tr>
<tr>
<td>10 μM NOC-18 + 50 μM ODQ</td>
<td>90.6 ± 1.7% (n.s.)</td>
</tr>
<tr>
<td>50 μM ODQ</td>
<td>90.0 ± 1.6% (n.s.)</td>
</tr>
<tr>
<td>24 h Control</td>
<td>90.6 ± 1.2%</td>
</tr>
<tr>
<td>10 μM NOC-18</td>
<td>91.0 ± 1.4% (n.s.)</td>
</tr>
<tr>
<td>10 μM NOC-18 + 1 μM U0126</td>
<td>90.1 ± 1.4% (n.s.)</td>
</tr>
<tr>
<td>1 μM U0126</td>
<td>89.8 ± 1.8% (n.s.)</td>
</tr>
<tr>
<td>10 μM NOC-18 + 50 μM ODQ</td>
<td>91.4 ± 1.1% (n.s.)</td>
</tr>
<tr>
<td>50 μM ODQ</td>
<td>90.5 ± 2.0% (n.s.)</td>
</tr>
</tbody>
</table>

Cell viability was assessed using the nuclear dye 7-AAD, detected by flow cytometry.

Data are expressed as means ± SEM of at least 3 independent experiments.

p > 0.05 (nonsignificant; n.s.), not different from control, one-way ANOVA (Dunnett’s post-test).

Table 2. Cell viability in neural stem cell cultures following exposure to NOC-18 with or without U0126 or ODQ
early activation of ERK1/2 by exogenous NO, since KT5823, a PKG inhibitor, did not prevent the increased phosphorylation of ERK1/2 following exposure to NOC-18 for 15 min (fig. 4c).

The cGMP Analogue 8-Br-cGMP Activates the ERK/MAPK Pathway via PKG

Since the cGMP analogue 8-Br-cGMP increased cell proliferation at 6 and 24 h in a similar manner to NOC-18,
we also investigated the ability of 8-Br-cGMP to activate the ERK pathway. We analyzed the phospho-ERK1/2:total ERK1/2 immunoreactivity ratio at 5, 15, 30, 60 and 120 min following treatment with 8-Br-cGMP. There was a steady increase in the levels of phosphorylated ERK1/2 up to 2 h after treatment. At this point time, 20 μM 8-Br-cGMP induced a two-fold increase in phospho-ERK1/2:total ERK1/2 immunoreactivity ratio (221.1 ± 12.3% of the control), as compared to untreated cultures (fig. 5a). Inhibition of PKG with KT5823 prevented ERK1/2 phosphorylation following exposure to 8-Br-cGMP for 2 h (fig. 5b), suggesting that PKG activation by 8-Br-cGMP is important for activation of ERK1/2 and occurs upstream of ERK1/2 phosphorylation. Likewise, the blockade of the ERK pathway by U0126 prevented EdU incorporation stimulated by treatment with 8-Br-cGMP for 6 h (102.9 ± 4.8%, p < 0.05; fig. 5c) or 24 h (87.0 ± 5.8%, p < 0.01; fig. 5d).
PKG Contributes to Late but Not to Early Proliferation Induced by NO

The involvement of PKG in the proliferative effect of NO was studied by flow cytometry by evaluating the incorporation of EdU by SVZ cell cultures following treatment with NOC-18 (10 μM) in the absence or presence of 1 μM KT5823, a selective PKG inhibitor, for 6 h (a) or 24 h (b), evaluated by incorporation of EdU and assessed by flow cytometry. Data are expressed as means ± SEM of at least 4 independent experiments. One-way ANOVA (Bonferroni’s post-test). *** p < 0.001, significantly different from control; ** p < 0.01, significantly different from NOC-18. EdU incorporation in neural stem cells following exposure to 8-Br-cGMP (20 μM) in the absence or presence of 1 μM KT5823, for 6 h (c) or 24 h (d), as assessed by flow cytometry. Data are expressed as means ± SEM of at least 4 independent experiments. One-way ANOVA (Bonferroni’s post-test). * p < 0.05 or ** p < 0.01, significantly different from control; * p < 0.05, significantly different from 8-Br-cGMP.

Flow cytometry analysis of nuclei stained with 7-AAD, for the treatments described above, showed that KT5823 alone or in combination with NOC-18 or 8-Br-cGMP did not significantly affect the cell viability of SVZ cells compared to untreated cultures (table 3).
In this work, we show that cGMP and PKG are involved in the late proliferative effect triggered by NO in neural stem cell cultures, since the inhibition of guanylyl cyclase or PKG abolishes cell proliferation induced by NO. Although cGMP and PKG were not involved in the early activation of ERK1/2, they were mandatory for the increase in cell proliferation following treatment with the NO donor NOC-18 at 6 h. Furthermore, we have previously shown that phosphorylation and activation of ERK1/2 is essential for the proliferative effect of NO, either at the early stages of cell proliferation following exposure to NO (as early as 30 min) or for later endpoints (24 h) [20]. These data strongly suggest that the initial proliferation triggered by NO is dependent on the activation of the ERK1/2 pathway, does not require activation of guanylyl cyclase, and is not dependent on cGMP.

Our results demonstrate that NO rapidly and transiently activates ERK1/2 in a cGMP-independent manner, since ODQ did not prevent ERK1/2 phosphorylation. Also, the blockade of guanylyl cyclase did not prevent the early proliferative effect of NOC-18 at 6 h. Furthermore, we also found that the crosstalk between the ERK1/2 pathway and the PKG pathway differs when neural stem cells are treated directly with the NO donor or with the cGMP analogue.

Cell viability was assessed using the nuclear dye 7-AAD, detected by flow cytometry. Data are expressed as means ± SEM of at least 3 independent experiments. p > 0.05 (nonsignificant; n.s.), not different from control, one-way ANOVA (Dunnett’s post-test).

### Table 3. Cell viability in neural stem cell cultures following exposure to NOC-18 or 8-Br-cGMP with or without KT5823

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Live cells (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>6 h</td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td>89.7 ± 1.1%</td>
</tr>
<tr>
<td>10 μM NOC-18</td>
<td>91.0 ± 1.9% (n.s.)</td>
</tr>
<tr>
<td>10 μM NOC-18 + 1 μM KT5823</td>
<td>92.2 ± 1.1% (n.s.)</td>
</tr>
<tr>
<td>20 μM 8-Br-cGMP</td>
<td>93.0 ± 1.2% (n.s.)</td>
</tr>
<tr>
<td>20 μM 8-Br-cGMP + 1 μM KT5823</td>
<td>90.2 ± 1.2% (n.s.)</td>
</tr>
<tr>
<td>1 μM KT5823</td>
<td>92.1 ± 1.3% (n.s.)</td>
</tr>
<tr>
<td>24 h Control</td>
<td>87.9 ± 1.9%</td>
</tr>
<tr>
<td>10 μM NOC-18</td>
<td>91.0 ± 2.1% (n.s.)</td>
</tr>
<tr>
<td>10 μM NOC-18 + 1 μM KT5823</td>
<td>92.1 ± 2.3% (n.s.)</td>
</tr>
<tr>
<td>20 μM 8-Br-cGMP</td>
<td>89.9 ± 0.8% (n.s.)</td>
</tr>
<tr>
<td>20 μM 8-Br-cGMP + 1 μM KT5823</td>
<td>90.0 ± 1.2% (n.s.)</td>
</tr>
<tr>
<td>1 μM KT5823</td>
<td>93.5 ± 1.1% (n.s.)</td>
</tr>
</tbody>
</table>

Discussion

In this work, we show that cGMP and PKG are involved in the late proliferative effect triggered by NO in neural stem cell cultures, since the inhibition of guanylyl cyclase or PKG abolishes cell proliferation induced by NO. Although cGMP and PKG were not involved in the early activation of ERK1/2, they were mandatory for the increase in cell proliferation following treatment with the NO donor NOC-18 for 24 h. Moreover, the cGMP analogue 8-Br-cGMP also increased neural stem cell proliferation. We also found that the crosstalk between the ERK1/2 pathway and the PKG pathway differs when neural stem cells are treated directly with the NO donor or with the cGMP analogue.

Our results demonstrate that NO rapidly and transiently activates ERK1/2 in a cGMP-independent manner, since ODQ did not prevent ERK1/2 phosphorylation. Also, the blockade of guanylyl cyclase did not prevent the early proliferative effect of NOC-18 at 6 h. Furthermore, we have previously shown that phosphorylation and activation of ERK1/2 is essential for the proliferative effect of NO, either at the early stages of cell proliferation following exposure to NO (as early as 30 min) or for later endpoints (24 h) [20]. These data strongly suggest that the initial proliferation triggered by NO is dependent on the activation of the ERK1/2 pathway, does not require activation of guanylyl cyclase, and is not dependent on cGMP. This early proliferative effect is also independent of PKG, which does not contribute to either ERK phosphorylation or proliferation. Possibly, NO might directly activate components of the ERK pathway (upstream of ERK1/2) that are sensitive to NO signaling by S-nitrosylation of cysteine residues. For instance, p21Ras has a cysteine residue (Cys118) that is sensitive to NO, and when nitrosylated, p21Ras becomes activated [31, 32].

Long-term exposure (24 h) to NO increased cell proliferation in a cGMP-dependent manner. The blockade of...
guanylyl cyclase or PKG completely abolished the proliferative effect of NO at 24 h, suggesting that cGMP and PKG signaling are essential for the proliferative effect of NO. Our data strongly suggest that the proliferative effect of NO is biphasic, i.e. an early increase in proliferation is dependent on the MAPK pathway and does not rely on guanylyl cyclase or PKG, and for later stages cGMP and PKG contribute heavily to the proliferation induced by NO. It is worth noting that the production of cGMP was independent of the MAPK pathway, since U0126 did not prevent the increase in cGMP levels observed following a 24-hour exposure to NOC-18.

The cGMP analogue 8-Br-cGMP also triggered cell proliferation, and our data show that PKG is important for this proliferative effect. 8-Br-cGMP also induced activation of ERK1/2, which was now sensitive to the inhibition of PKG, suggesting that phosphorylation of ERK1/2 following 8-Br-cGMP application to neural stem cells relies on a mechanism dependent on PKG. It remains to be established whether PKG directly activates ERK by phosphorylation. Furthermore, we observed that blocking ERK1/2 activation with U0126 prevents proliferation of neural stem cells following treatment with 8-Br-cGMP, suggesting that the activation of the MAPK pathway is responsible for the proliferative effect of the cGMP analogue. PKG is a serine/threonine kinase that is activated upon binding of cGMP, and NO-induced elevation of the intracellular levels of cGMP has been reported to directly regulate the activity of PKG [33–35]. PKG has been implicated in the regulation of gene expression as reviewed by Madhusoodanan and Murad [23]. Some studies suggest that the cGMP/PKG pathway is involved in the activation of the MAPK pathway, particularly ERK1/2 [36, 37], which appears to be the case in our study where neural stem cells are treated with a cGMP analogue. When the neural stem cells are treated with a NO donor, we observed that the initial ERK1/2 activation is independent of cGMP-dependent signaling to initiate the early proliferative events triggered by NO. For longer exposures, signaling via guanylyl cyclase and PKG gains relevance for the proliferation stimulated by NO.

The GC-cGMP pathway is the main effector pathway of the biological effects of NO as a second messenger. Although this pathway is expected to participate in the signaling events contributing to the proliferative effect of NO treatment in neural stem cells, most evidence up to now was circumstantial. Regarding the formation of newborn cells from stem cells, it was reported that the elevation of cGMP levels by PDE5 inhibition promoted PKG activation, enhancing the proliferation of mesenchymal stem cells [38]. Other studies correlated the elevation of cGMP levels with the enhancement of neurogenesis [25, 26, 39]. Understanding how cGMP and its downstream target PKG contribute to the proliferative effect of NO can help in better targeting these systems to design well-grounded therapies for stimulating endogenous neurogenesis for brain repair purposes.

Altogether, we show that NO can activate two independent pathways in a biphasic manner that act to increase neural stem cell proliferation, initially the ERK/MAPK pathway, and for later stages the guanylyl/cGMP/PKG pathway. Although there is no evidence of crosstalk between these two pathways for the early effect of NO, this possibility cannot be excluded for NO-induced cell proliferation at later stages. While the early proliferation of neural stem cells triggered by NO is independent of cGMP and PKG, the complete blockade of the proliferative effect of NO at later stages by inhibition of either guanylyl cyclase, PKG or ERK1/2 suggests a crosstalk between these different signaling pathways.

Acknowledgments

This work was supported by the Calouste Gulbenkian Foundation, L’Oréal, UNESCO, and the Foundation for Science and Technology (FCT, Portugal), COMPETE and FEDER (project PTDC/SAU-NEU/102612/2008). Bruno P. Carreira and Maria Inês Morte were supported by FCT, Portugal (fellowships SFRH/BPD/78901/2011, SFRH/BD/23754/2005 and SFRH/BD/38127/2007).

References

Biphasic Stimulation of Neural Stem Cell Proliferation by NO

DOI: 10.1159/000332811